ArticleThe Journal of experimental medicine1990
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.
Article in The Journal of experimental medicine, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed, 841 citations in OpenAlex.
- The impact of METTL3 on bladder cancer through mFrontiers in oncology · 2025Review
- Review
- EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis.Journal of thrombosis and thrombolysis · 2024Article
- Reduced Angiopoietin Factor 2 Levels Are Correlated with Better Cardiac Function and Prognosis in Valvular Heart Disease.Brazilian journal of cardiovascular surgery · 2023Article
- The Intricate Role of Non-Coding RNAs in Sepsis-Associated Disseminated Intravascular Coagulation.International journal of molecular sciences · 2023Review
- Thrombosis, cancer, and COVID-19.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Serum VEGF-C as an evaluation marker of disease activity in adult-onset Still's disease.Rheumatology international · 2022Observational
- The innate immune system in diabetic retinopathy.Progress in retinal and eye research · 2021Review
- IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes.International journal of molecular sciences · 2021Review
- The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.Cancers · 2021Review
- Protease-activated receptor 1 as a potential therapeutic target for COVID-19.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Dicer Enhances Bevacizumab-Related Inhibition of Hepatocellular Carcinoma via Blocking the Vascular Endothelial Growth Factor Pathway.Journal of hepatocellular carcinoma · 2021Article
- Coagulation in Lymphatic System.Frontiers in cardiovascular medicine · 2021Review
- Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer.Frontiers in immunology · 2021Review
- Mast cells and angiogenesis in multiple sclerosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- Thrombosis and Hemostasis Issues in Cancer Patients with COVID-19.Seminars in thrombosis and hemostasis · 2020Review
- Gene-activated dermal equivalents to accelerate healing of diabetic chronic wounds by regulating inflammation and promoting angiogenesis.Bioactive materials · 2020Article
- Platelets and Metastasis: New Implications of an Old Interplay.Frontiers in oncology · 2020Review
- Maternal Flt-1 and endoglin expression by circulating monocyte subtype and polarization in preeclampsia and fetal growth restriction.European journal of obstetrics & gynecology and reproductive biology: X · 2019Article
- Bi-layer blood vessel mimicking microfluidic platform for antitumor drug screening based on co-culturing 3D tumor spheroids and endothelial layers.Biomicrofluidics · 2019Article
110 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Systemic infusion of low concentrations of tumor necrosis factor/cachectin (TNF) into mice that bear TNF-sensitive tumors leads to activation of coagulation, fibrin formation, and occlusive thrombosis exclusively within the tumor vascular bed. To identify mechanisms underlying the localization of this vascular procoagulant response, a tumor-derived polypeptide has been purified to homogeneity from supernatants of murine methylcholanthrene A-induced fibrosarcomas that induces endothelial tissue factor synthesis and expression (half-maximal response at approximately 300 pM), and augments the procoagulant response to TNF in a synergistic fashion. This tumor-derived polypeptide was identified as the murine homologue of vascular permeability factor (VPF) based on similar mobility on SDS-PAGE, an homologous NH2-terminal amino acid sequence, and recognition by a monospecific antibody to guinea pig VPF. In addition, VPF was shown to induce monocyte activation, as evidenced by expression of tissue factor. Finally, VPF was shown to induce monocyte chemotaxis across collagen membranes and endothelial cell monolayers. Taken together, these results indicate that VPF can modulate the coagulant properties of endothelium and monocytes, and can promote monocyte migration into the tumor bed. This suggests one mechanism through which tumor-derived mediators can alter properties of the vessel wall.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.